This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in ...

The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...

Medtronic is a Dividend Aristocrat with 47 consecutive years of payout growth. The MedTech company exceeded the analyst consensus for revenue and non-GAAP EPS in its fiscal first quarter ...

Today, Medtronic plc (NYSE:MDT), a leader in medical technology, announced the outcomes of its 2024 Annual General Meeting held on Thursday. Shareholders voted on several key proposals ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

The next wave could grow the market further. Medtronic has received Food and Drug Administration approval to study its Affera mapping and ablation system and Sphere-9 catheter to treat sustained ...